Opinion|Videos|February 17, 2025
Bispecific Antibodies in the Relapsed/Refractory DLBCL Treatment Landscape
A discussion of major challenges in using bispecific antibodies in the relapsed/refractory DLBCL setting, focusing on dosing, safety concerns like CRS, and step-up dosing strategies, along with insights on best practices for community clinics; followed by a review of sequencing bispecific antibodies and CAR T-cell therapies in third-line treatment, informed by recent studies on bispecific/CAR T sequencing
Advertisement
Video content above is prompted by the following:
What are major challenges present when using bispecific antibodies in the RR setting of DLBCL?
- Please discuss challenges associated with dosing as well as safety concerns and discuss how they can be managed.
- Step-up dosing (
Dickinson et al. NEJM 2022 ); CRS (Falchi et al. ASH 2023 )
- Step-up dosing (
- What insights can you offer community clinics with regards to best practices when using and initiating bispecific antibodies?
ALL: Please share your thoughts on sequencing bispecific antibodies in the 3L setting.
- Review bispecific/CAR T sequencing and share your thoughts:
Haydu and Abramson Blood Adv 2024 ;Haynes et al. ASH 2024
Advertisement
Related to this article
Robert A. Winn, MD, discussed his path to becoming a physician, scientist, and leader at Fox Chase Cancer Center.
Updated analyses from a phase 2a study suggest durable survival with namodenosen in a subset of heavily pretreated patients with advanced PDAC.
Need a refresh on the current regulatory landscape for GI oncology? We've got you covered. Here's everything that moved the needle across GI malignancies this month.
Toni Choueiri, MD, discusses the clinical significance of the FDA approval of adjuvant belzutifan plus pembrolizumab in ccRCC.
Panelists discuss how nodal burden, NGS turnaround time, and regional resource heterogeneity shape treatment sequencing in EGFR-mutated NSCLC in Latin America.
Zanubrutinib plus R-BAP produced responses in both younger and older patients with previously untreated mantle cell lymphoma.
Breast oncologists weigh the future role of radiographic progression vs liquid biopsy in the timing of therapeutic shifts in metastatic breast cancer.
Sylvester cancer researchers became wildland firefighters themselves to study, from the inside, cancer risks tied to the job.
Advertisement
Advertisement
Trending on OncLive
1
June’s GI Rewind: CRC, Gastric Cancer See Several “Firsts” With FDA Review of Adjuvant IO, Global Approval of BRAF-Targeted and CAR T-Cell Therapies
2
SERENA-6 Controversies Push the Breast Cancer Field to Consider the Future Role of ctDNA-Guided Treatment Decisions
3
Namodenoson Meets Safety End Point in PDAC, Shows Durable Survival Outcomes Pretreated Subgroup
4
FDA Approval Positions Belzutifan Plus Pembrolizumab as a New Adjuvant Standard in ccRCC
5